dc.contributor.authors |
Gozdas, HT; Karabay, O; |
|
dc.date.accessioned |
2020-02-27T08:44:41Z |
|
dc.date.available |
2020-02-27T08:44:41Z |
|
dc.date.issued |
2015 |
|
dc.identifier.citation |
Gozdas, HT; Karabay, O; (2015). Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment. INDIAN JOURNAL OF PHARMACOLOGY, 47, 122-121 |
|
dc.identifier.issn |
0253-7613 |
|
dc.identifier.uri |
https://doi.org/10.4103/0253-7613.150377 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/66829 |
|
dc.description.abstract |
Peginterferon alpha-2a (PEG IFN -2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN -2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN -2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug. |
|
dc.language |
English |
|
dc.publisher |
WOLTERS KLUWER MEDKNOW PUBLICATIONS |
|
dc.subject |
Pharmacology & Pharmacy |
|
dc.title |
Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment |
|
dc.type |
Article |
|
dc.identifier.volume |
47 |
|
dc.identifier.startpage |
121 |
|
dc.identifier.endpage |
122 |
|
dc.contributor.department |
Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü |
|
dc.contributor.saüauthor |
Karabay, Oğuz |
|
dc.relation.journal |
INDIAN JOURNAL OF PHARMACOLOGY |
|
dc.identifier.wos |
WOS:000349144300024 |
|
dc.identifier.doi |
10.4103/0253-7613.150377 |
|
dc.identifier.eissn |
1998-3751 |
|
dc.contributor.author |
Hasan Tahsin Gozdas |
|
dc.contributor.author |
Karabay, Oğuz |
|